-
Li Zhengqing, Senior Vice President Global and President of Research and Development in China at Merck: Nine valent HPV vaccine adds a second dose vaccination program for women aged 9-14, and Merck "increases efforts" to eliminate cervical cancer
On January 9, 2024, MSD announced that its second dose vaccination program for the nine valent human papillomavirus (HPV) vaccine targeting women aged 9-14 has been approved by the National Medical P ...